PROMO.ST Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (16 Jan 2024 @ 11:21):

Stats
Today's Volume	1.12M
Average Volume	2.06M
Market Cap	293.55M
EPS	SEK-0.0643 ( 2023-09-30 )
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-0.314
ATR14	SEK5.16 (36.49%)

Volume Correlation

Long: -0.10 (neutral)

Short: 0.27 (neutral)

Signal:(45.746) Neutral

Promore Pharma AB (publ) Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Promore Pharma AB (publ) Correlation - Currency/Commodity

0.52
( weak )

0.48
( neutral )

-0.36
( neutral )

0.52
( weak )

0.26
( neutral )

-0.11
( neutral )

Promore Pharma AB (publ) Financials

Annual	2022
Revenue:	SEK99 000.00
Gross Profit:	SEK-15.85M (-16 005.05 %)
EPS:	SEK-0.440

Q3	2023
Revenue:	SEK0
Gross Profit:	SEK-1.37M (0.00 %)
EPS:	SEK-0.0643

Q2	2023
Revenue:	SEK126 000
Gross Profit:	SEK-1.22M (-965.08 %)
EPS:	SEK-0.0616

Q1	2023
Revenue:	SEK34 000.00
Gross Profit:	SEK-4.90M (-14 397.06 %)
EPS:	SEK-0.120

Financial Reports:

No articles found.

Promore Pharma AB (publ)

Promore Pharma AB (publ), a biopharmaceutical company, develops peptide-based drug candidates in Sweden and internationally. Its product candidates include PXL01 that is in Phase IIa study for the prevention of post-surgical adhesions and scars, and for the prevention of dermal scars, as well as for tendon repair surgery in the hand; and LL-37, which is in Phase IIb clinical studies for treating patients with venous leg ulcers, stimulate the healing of chronic wounds, and for the treatment of diabetic foot ulcers. It entered into a cooperation agreement with Fidia Farmaceutici S.p.A. for the production of hyaluronic acid syringes. The company was formerly known as Lipopeptide AB and changed its name to Promore Pharma AB (publ) in January 2017. Promore Pharma AB (publ) was founded in 2002 and is headquartered in Solna, Sweden.